



Model List of Essential Medicines

Abemaciclib

Section	Indications
Targeted therapies	Therapeutic equivalent to palbociclib for Other specified malignant neoplasms of breast

Afatinib

Section	Indications
Targeted therapies	Therapeutic equivalent to erlotinib for Other specified malignant neoplasms of bronchus or lung

All-trans retinoic acid

Section	Indications
Targeted therapies Oral > Solid: 10 mg capsule	Acute myeloid leukaemia with recurrent genetic abnormalities

Binimetinib

Section	Indications
Targeted therapies	Therapeutic equivalent to trametinib for Other specified melanoma of skin

Bortezomib

Section	Indications
Targeted therapies Parenteral > General injections > unspecified: 3.5 mg in vial powder for injection	Plasma cell myeloma

Cobimetinib

Section	Indications
Targeted therapies	Therapeutic equivalent to trametinib for Other specified melanoma of skin

Crizotinib

Section	Indications
Targeted therapies	Other specified malignant neoplasms of bronchus or lung
Oral > Solid: 200 mg; 250 mg Oral > Solid > capsule: 200 mg; 250 mg	Anaplastic large cell lymphoma, ALK-positive

Dabrafenib

Section	Indications
Targeted therapies	Other specified melanoma of skin
Oral > Solid: 50 mg; 75 mg	

Dasatinib

Section	Indications
Targeted therapies	Chronic myeloid leukaemia, not elsewhere classified
Oral > Solid: 20 mg tablet; 50 mg tablet; 70 mg tablet; 80 mg tablet; 100 mg tablet; 140 mg tablet	

Encorafenib

Section	Indications
Targeted therapies	Therapeutic equivalent to dabrafenib for Other specified melanoma of skin

Erlotinib

Section	Indications
Targeted therapies	Other specified malignant neoplasms of bronchus or lung
Oral > Solid: 100 mg; 150 mg	

Everolimus

Section	Indications
Targeted therapies	Other specified gliomas of brain
Oral > Solid > dispersible tablet: 2 mg; 3 mg; 5 mg	
Oral > Solid > tablet: 2.5 mg; 5 mg; 7.5 mg; 10 mg	

Gefitinib

Section	Indications
Targeted therapies	Therapeutic equivalent to erlotinib for Other specified malignant neoplasms of bronchus or lung

Ibrutinib

Section	Indications
Targeted therapies Oral > Solid: 140 mg	Chronic lymphocytic leukaemia or small lymphocytic lymphoma

Imatinib

Section	Indications
Targeted therapies Oral > Solid: 100 mg; 400 mg	B lymphoblastic leukaemia or lymphoma with t(9;22) (q34;q11.2); BCR-ABL1 Gastrointestinal stromal tumour of unspecified gastrointestinal sites Chronic myeloid leukaemia, not elsewhere classified

Nilotinib

Section	Indications
Targeted therapies Oral > Solid > capsule: 150 mg; 200 mg	Chronic myeloid leukaemia, not elsewhere classified

Osimertinib

Section	Indications
Targeted therapies Oral > Solid: 40 mg (as mesylate); 80 mg (as mesylate)	Other specified malignant neoplasms of bronchus or lung

Palbociclib

Section	Indications
Targeted therapies Oral > Solid: 75 mg; 100 mg; 125 mg	Other specified malignant neoplasms of breast

Pertuzumab

Section	Indications
<p>Targeted therapies Parenteral > General injections > IV: 240 mg per 14 mL in vial concentrated solution</p>	Carcinoma of breast, specialised type

Ribociclib

Section	Indications
<p>Targeted therapies</p>	Therapeutic equivalent to palbociclib for Other specified malignant neoplasms of breast

Rituximab

Section	Indications
<p>Targeted therapies Parenteral > General injections > IV: 100 mg per 10 mL in 10 mL vial; 500 mg per 50 mL in 50 mL vial</p>	Follicular lymphoma Chronic lymphocytic leukaemia or small lymphocytic lymphoma Diffuse large B-cell lymphomas Burkitt lymphoma including Burkitt leukaemia

Trametinib

Section	Indications
<p>Targeted therapies Oral > Solid: 0.5 mg; 2 mg</p>	Other specified melanoma of skin

Trastuzumab

Section	Indications
<p>Targeted therapies Parenteral > General injections > IV: 60 mg in vial powder for injection; 150 mg in vial powder for injection; 440 mg in vial powder for injection</p>	Carcinoma of breast, specialised type

Trastuzumab emtansine

Section	Indications
<p>Targeted therapies Parenteral > General injections > IV: 100 mg in vial powder for injection; 160 mg in vial powder for injection</p>	Carcinoma of breast, specialised type

Vemurafenib

Section	Indications
Targeted therapies	Therapeutic equivalent to dabrafenib for Other specified melanoma of skin

Zanubrutinib

Section	Indications
Targeted therapies Oral > Solid: 80 mg	Mantle cell lymphoma Chronic lymphocytic leukaemia or small lymphocytic lymphoma